Quality control of anti-tuberculosis FDC formulations in the global market: Part II-accelerated stability studies

International Journal of Tuberculosis and Lung Disease

Volumn 9, Issue 11, 2005, Pages 1266-1272

  Ashokraj, Y ^a   Kohli, G ^a   Kaul, C L ^a   Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Accelerated stability test; Dissolution; Fixeddose combination; Rifampicin; Tuberculosis

Indexed keywords

AKURIT 4; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; RIMSTAR; TUBERCULOSTATIC AGENT;

ARTICLE; DISSOLUTION; DRUG FORMULATION; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; DRUG STABILITY; DRUG STORAGE; HUMIDITY; MEDICAL LITERATURE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; TABLET;

ANTIBIOTICS, ANTITUBERCULAR; DRUG COMBINATIONS; DRUG STABILITY; QUALITY CONTROL; RIFAMPIN; TIME FACTORS;

EID: 28444449882     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Pillai G, Fourie P B, Padyatchi N, et al. Recent bioequivalence studies on fixed dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-S316.
2. McIlleron H, Wash P, Burger A, et al. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361.
3. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm 2004; 287: 97-112.
4. Ashokraj Y, Agrawal S, Varma M V S, et al. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study. Int J Tuberc Lung Dis 2004; 8: 1081-1088.
5. International Conference on Harmonization. ICH harmonized tripartite guideline. Stability testing of new drug substances and products. ICH Steering Committee. 6 February 2003. Geneva, Switzerland: ICH, 2003.
6. United States Pharmacopoeia. Rifampicin and isoniazid capsules. USP 26. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp 1643.
7. United States Pharmacopoeia. Rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets. USP 26. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp 1645.
8. United States Pharmacopoeia. Rifampicin capsules. USP 26. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp 1640-1641.
9. United States Pharmacopoeia. Uniformity of content. USP 24. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp 2001-2003.
10. Risha P G, Shewiyo D, Msami A, et al. In vitro evaluation of the quality of essential drugs on the Tanzanian market. Trop Med Int Health. 2002; 7: 701-707.
11. Kayumba P C, Risha P G, Shewiyo D, et al. The quality of essential antimicrobial and antimalarial drugs marketed in Rwanda and Tanzania: influence of tropical storage conditions on in vitro dissolution. J Clin Pharm Ther 2004; 29: 331-338.
12. Ballereau F, Prazuck T, Schrive I, et al. Stability of essential drugs in the field: results of a study conducted over a two-year period in Burkina Faso. Am J Trop Med Hyg 1997; 57: 31-36.
13. Pecanac D, Van Houtte F, Roets E, et al. A stability study of ticlopidine products from 18 countries. Drug Dev Ind Pharm 2000; 26: 391-401.
14. Yoshioka S, Carstensen J T. Rational storage conditions for accelerated testing of stability of solid pharmaceuticals. J Pharm Sci 1990; 79: 943-944.
15. Allinson J G, Dansereau R J, Sakr A. The effects of packaging on the stability of a moisture sensitive compound. Int J Pharm 200; 221: 49-56.